Brickworks (ASX:BKW) maintains an impressive 47-year streak

Nick Sundich Nick Sundich, March 23, 2023

Brickworks (ASX:BKW) has achieved a feat that few other ASX companies have: maintaining or increasing dividends for 47 years in a row. It released 1HY23 results this morning and recorded an NPAT of $410m.  

 

 

No time to do stock research, but you still want to invest?

 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 
BKW records a solid result

BKW generated $584m in revenue (up 13%), $569m in EBIT (up 26%) and a $410m underlying NPAT (up 24%). It paid a dividend of 23c per share, yielding 1.9% on an annualised basis and thereby keeping the streak alive. 

Ironically, this was not achieved merely through the company’s core brick-making operatings. 

 

Property helps

Brickworks has a strategic stake in Washington Soul Pattinson (ASX:SOL) and also interests in industrial property. A $301m sale of Oakdale East into the Industrial Joint Venture Trust delivered earnings of $263m and boosted the Net Asset Value of Property Trusts to $2.2bn. 

Turning to Building Products, North American EBITDA was up 16% to $14m but down 6% to $50m in Australia. The company blamed a backlog of work from government stimulus, labour market tightness and supply chain issues. 

 

 

Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
 
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

aml3d

AML3D Surges After Landing 9th US Order with A$1.7m ARCEMY X Deal

AML3D Extends US Momentum, Stock Rises on Major A$1.69m ARCEMY X Sale to FasTech AML3D (ASX: AL3) continues to build…

metallium

Metallium Signs Binding 10 Year Deal with New Frontier Minerals After Record Processing Results

Record FJH Results Drive Metallium’s Binding Ten-Year Deal with New Frontier Minerals Metallium (ASX: MTM) delivered a major step forward…

Prescient Therapeutics

Prescient Therapeutics (ASX:PTX): It has taken the plunge into a Phase 2 trial against T-Cell Lymphoma

There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…